UK Chancellor Healey said the next International Investment Summit will be held in spring.

UK Office for Budget Responsibility (OBR) forecasts GDP growth of 1.2% in 2026 (March: 1.1%); 1.0% in 2027 (March: 1.6%); 1.6% in 2028 (March: 1.6%); 1.8% in 2029 (March: 1.5%); and 1.7% in 2030 (March: 1.5%).

Jiangsu Hengrui Medicine Co., Ltd said its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd has received an approval notice from the National Medical Products Administration to begin clinical trials of HRS-2189 tablets and will start trials shortly. HRS-2189 is a novel KAT6 inhibitor that downregulates oncogene expression by inhibiting histone lysine acetylation and is being developed for advanced malignant tumors. No other KAT6-targeting drug is currently approved domestically or abroad. R&D investment in the HRS-2189 program to date totals about 55.3 mln yuan.